Psyched Wellness Launches Calmer, a 2x Version of Calm and an Enhanced Flavour Profile for Calm

Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company specializing in the production and distribution of dietary supplements derived from the Amanita Muscaria mushroom, is pleased to announce the launch of Calmer, a new product offering that delivers twice the potency of its flagship product, Calm.

The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025.

Jeffrey Stevens, CEO of Psyched Wellness, commented:

"We are thrilled to launch Calmer, a 2x version of Calm. We listened to the feedback of our monthly subscribers, who expressed a desire for a more potent version. After months of R&D, our team successfully concentrated AME-1 without compromising potency or experience. In addition to R&D on Calmer, we worked on improving the flavour profile of Calm, resulting in a smoother taste while maintaining the potency and experience."

Psyched Wellness continues to expand its route-to-market partnerships across Canada and the United States. Interested distributors or retailers are encouraged to contact the Company at **sales@psyched-wellness.com**.

Psyched Wellness will be growing their route-to-market partnerships, throughout the nation. If you are interested in distributing/listing Calm, please reach out to sales@psyched-wellness.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based dietary supplements company dedicated to researching and producing consumer packaged goods product derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "proposed", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to achieve its scheduled production runs; Company's expectations regarding regulatory compliance and market introduction of AME-1; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; continued support of safety and risk assessments to support the Company's evaluation of its products; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276093